Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod

[1]  B. Penninx,et al.  Serum BDNF Concentrations Show Strong Seasonal Variation and Correlations with the Amount of Ambient Sunlight , 2012, PloS one.

[2]  R. Saada,et al.  Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis , 2012, Journal of Neuroimmunology.

[3]  Ariel Miller,et al.  Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis , 2012, Journal of Neuroimmunology.

[4]  G. Pizzolato,et al.  Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis , 2012, Journal of the Neurological Sciences.

[5]  V. Yong,et al.  Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. , 2012, The American journal of pathology.

[6]  C. Wegner,et al.  Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination , 2012, Acta Neuropathologica.

[7]  R. Sobel,et al.  Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity , 2012, PloS one.

[8]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[9]  C. Wegner,et al.  Insight into the mechanism of laquinimod action , 2011, Journal of the Neurological Sciences.

[10]  J. Cracowski,et al.  C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. , 2011, Arthritis and rheumatism.

[11]  C. Wegner,et al.  Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[12]  M. Filippi,et al.  Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study , 2010, Multiple sclerosis.

[13]  T. Tuller,et al.  Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: In-vitro high-throughput gene expression study , 2010, Journal of Neuroimmunology.

[14]  S. Dhib-jalbut,et al.  Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.

[15]  Nitin J. Karandikar,et al.  The mechanism of action of glatiramer acetate treatment in multiple sclerosis , 2010, Neurology.

[16]  E. Andrès,et al.  CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.

[17]  G. Comi,et al.  Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[18]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[19]  T. Leanderson,et al.  Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice , 2006, Journal of Neuroimmunology.

[20]  A. Karni,et al.  Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate , 2005, Journal of Neuroimmunology.

[21]  F. Barkhof,et al.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.

[22]  G. Hedlund,et al.  Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats , 2004, Journal of Neuroimmunology.

[23]  S. Groshen,et al.  Increased CXCL8 (IL-8) expression in Multiple Sclerosis , 2004, Journal of Neuroimmunology.

[24]  C. Piccirillo,et al.  Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. , 2004, Trends in immunology.

[25]  G. Hedlund,et al.  Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. , 2004, Journal of medicinal chemistry.

[26]  M. Zhan,et al.  Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype , 2003, Journal of Neuroimmunology.

[27]  V. Gallai†,et al.  Brain-derived neurotrophic factor in patients with multiple sclerosis , 2002, Journal of Neuroimmunology.

[28]  F. Fazekas,et al.  Statins as immunomodulators: Comparison with interferon-&bgr;1b in MS , 2002, Neurology.

[29]  G. Hedlund,et al.  The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[30]  B. Winblad,et al.  Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue , 2002, Neuropharmacology.

[31]  J. Krieger,et al.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.

[32]  P. Rieckmann,et al.  Effect of interferon β on human myelin basic protein–specific T-cell lines: Comparison of IFNβ-1a and IFNβ-1b , 1999 .

[33]  Ariel Miller,et al.  Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation , 1998, Journal of Neuroimmunology.

[34]  G. Marshall,et al.  Interferon-beta sub 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis , 1996, Neurology.

[35]  D. Jewell,et al.  Lymphocyte subset reference ranges in adult Caucasians. , 1991, Clinical immunology and immunopathology.

[36]  G. Comi,et al.  Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. , 2012, The American journal of pathology.

[37]  S. Ziegler,et al.  The activation antigen CD69 , 1994, Stem cells.